Colliers Securities analyst Kyle Bauser reiterated a Buy rating on Myomo (MYO – Research Report) today and set a price target of $17.00. The company’s shares closed last Monday at $7.63, close to its 52-week low of $6.36.
According to TipRanks.com, Bauser is a 2-star analyst with an average return of 0.3% and a 45.5% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Apollo Medical Holdings, Chembio Diagnostics, and Semler Scientific.
Myomo has an analyst consensus of Moderate Buy, with a price target consensus of $17.00.
Myomo’s market cap is currently $48.91M and has a P/E ratio of -4.04.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MYO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Myomo, Inc. is a medical robotics company, which offers expanded mobility for those suffering from neurological disorders and upper-limb paralysis. It offers MyoPro, which is a myoelectric elbow, wrist, and hand orthosis that supports an impaired hand and arm while also enabling it to move again. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Cambridge, MA.
Read More on MYO: